Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT06082570 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients

Start date: October 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-labeled, single-arm, multiple-dose escalation and single-dose expansion clinical study of cell therapy to observe and evaluate the safety and efficacy of c610 injection in the treatment of patients with advanced solid tumors.

NCT ID: NCT06047431 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of QL1706H in Patients With Advanced Solid Tumors

Start date: October 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase Ⅰ study of QL1706H in patients with advanced solid tumors. The study will evaluate the pharmacokenetics, safety, tolerability and preliminary efficacy of QL1706H.

NCT ID: NCT06026501 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Start date: August 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a one-arm, open, multicenter phase 1b/2 clinical trial of PE0116combined with PE0105 in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D and observing the preliminary efficacy.The trial can be divided into two parts: dose escalation part and expansion part.PE0105 is administered as a fixed-dose intravenous injection(3mg/kg Q3w).

NCT ID: NCT05951608 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Start date: July 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors

NCT ID: NCT05942378 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study evaluating the efficacy and safety of HRXG-K-1939 in combination with Adebrelimab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in patients with advanced solid tumors. HRXG-K-1939 will be administered to patients in a dose escalation regimen to determine a recommended dose for expansion.

NCT ID: NCT05906537 Not yet recruiting - Clinical trials for Advanced Solid Tumors

SKB410 for Injection in Solid Tumors

Start date: June 30, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.

NCT ID: NCT05830045 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors

Start date: April 20, 2023
Phase: Phase 1
Study type: Interventional

This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.

NCT ID: NCT05804864 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of KM501 in Patients With Solid Tumors

Start date: April 2023
Phase: Phase 1
Study type: Interventional

A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate HER2

NCT ID: NCT05781048 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

Start date: April 2023
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the efficacy, andsafety of HRS-6209in subjects with advanced solid tumors.To explore the reasonable dosage of HRS-6209.This study also preliminarily evaluated the efficacy of HRS-6209 in patients with advanced solid tumors.

NCT ID: NCT05718219 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Escalating Doses of SIM0348 as a Single Agent in Advanced Solid Tumors

Start date: April 1, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open label, phase I trial to evaluate the safety and tolerability, pharmacokinetic/ pharmacodynamic characteristics and to assess the preliminary efficacy of SIM0348 as monotherapy in adult subjects with advanced and metastatic solid tumors. The trial starts with a dose escalation and dose expansion part (Part 1) followed by a cohort expansion part (Part 2).